<DOC>
	<DOC>NCT01001195</DOC>
	<brief_summary>This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGANÂ®).</brief_summary>
	<brief_title>Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Ocular hypertension or primary openangle glaucoma in each eye Patient requires IOP lowering medication in each eye Ocular hyperemia or other ocular surface findings in either eye Active ocular disease Current or anticipated use of any topical ocular medication (including artificial tears) during the study Intraocular surgery within past six months or unilateral cataract surgery. Functionally significant visual field loss Anticipated wearing of contact lenses during study Use of other medications that affect IOP such as glaucoma treating medications, within 2 months of screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>